Brain 6-[F-18]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography

被引:11
作者
Nagasawa, H
Tanji, H
Itoyama, Y
Saito, H
Kimura, I
Fujiwara, T
Iwata, R
Itoh, M
Ido, T
机构
[1] MIYAGI NATL HOSP,DEPT NEUROL,SENDAI,MIYAGI,JAPAN
[2] NATL NISHI SAPPORO HOSP,SENDAI,MIYAGI,JAPAN
[3] YAMAGATA NATL HOSP,YAMAGATA,JAPAN
[4] TOHOKU UNIV,CTR CYCLOTRON & RADIOISOTOPE,SENDAI,MIYAGI 980,JAPAN
关键词
early and late onset Parkinson's disease; 6-[F-18]fluorodopa metabolism; positron emission tomography; nigrostriatal system;
D O I
10.1016/S0022-510X(96)00168-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We measured 6-[F-18]fluorodopa (FDOPA) uptake in the caudate nucleus and the putamen of 20 patients with early and late onset of Parkinson's disease (EOPD and LOPD) and 20 normal control subjects using positron emission tomography. The mean influx rate constant values (K-i) were significantly reduced in the caudate nucleus and the putamen of the patients with EOPD and LOPD compared with age-matched control groups (p < 0.01), respectively. There were significant negative correlations between K-i values in the caudate nucleus (r = -0.67, p = 0.0024) and the putamen (r = -0.67, p = 0.0014), and duration of disease in the LOPD group compared with the EOPD group. Similar negative relationships between K-i values and clinical stages by Hoehn and Yahr and degrees of main clinical symptoms (bradykinesia, tremor and rigidity) were more markedly seen in the LOPD group than in the EOPD group, The present results suggest that the function of presynaptic dopaminergic terminals correlates well with clinical disease severity and degrees of main symptoms in the LOPD group, but not in the EOPD group. We speculate that compensatory up-regulatory function in the postsynaptic dopaminergic receptors may modify disease severity and the degrees of main clinical symptoms of EOPD.
引用
收藏
页码:70 / 76
页数:7
相关论文
共 24 条
[1]
ADAM MJ, 1985, J NUCL MED, V26, P125
[2]
[C-11] RACLOPRIDE AND POSITRON EMISSION TOMOGRAPHY IN PREVIOUSLY UNTREATED PATIENTS WITH PARKINSONS-DISEASE - INFLUENCE OF L-DOPA AND LISURIDE THERAPY ON STRIATAL DOPAMINE D-2-RECEPTORS [J].
ANTONINI, A ;
SCHWARZ, J ;
OERTEL, WH ;
BEER, HF ;
MADEJA, UD ;
LEENDERS, KL .
NEUROLOGY, 1994, 44 (07) :1325-1329
[3]
BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
[4]
STRIATAL D2 RECEPTOR STATUS IN PATIENTS WITH PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION, AND PROGRESSIVE SUPRANUCLEAR PALSY, MEASURED WITH C-11 RACLOPRIDE AND POSITRON EMISSION TOMOGRAPHY [J].
BROOKS, DJ ;
IBANEZ, V ;
SAWLE, GV ;
PLAYFORD, ED ;
QUINN, N ;
MATHIAS, CJ ;
LEES, AJ ;
MARSDEN, CD ;
BANNISTER, R ;
FRACKOWIAK, RSJ .
ANNALS OF NEUROLOGY, 1992, 31 (02) :184-192
[5]
EVIDENCE FOR PLASTICITY OF THE DOPAMINERGIC SYSTEM IN PARKINSONISM [J].
DONNAN, GA ;
WOODHOUSE, DG ;
KACZMARCZYK, SJ ;
HOLDER, JE ;
PAXINOS, G ;
CHILCO, PJ ;
CHURCHYARD, AJ ;
KALNINS, RM ;
FABINY, GCA ;
MENDELSOHN, FAO .
MOLECULAR NEUROBIOLOGY, 1991, 5 (2-4) :421-433
[6]
MOTOR FLUCTUATIONS IN PARKINSONS-DISEASE - CENTRAL PATHOPHYSIOLOGICAL MECHANISMS .1. [J].
FABBRINI, G ;
MOURADIAN, MM ;
JUNCOS, JL ;
SCHLEGEL, J ;
MOHR, E ;
CHASE, TN .
ANNALS OF NEUROLOGY, 1988, 24 (03) :366-371
[7]
CEREBRAL METABOLISM OF 6-[F-18]FLUORO-L-3,4-DIHYDROXYPHENYLALANINE IN THE PRIMATE [J].
FIRNAU, G ;
SOOD, S ;
CHIRAKAL, R ;
NAHMIAS, C ;
GARNETT, ES .
JOURNAL OF NEUROCHEMISTRY, 1987, 48 (04) :1077-1082
[8]
DOPAMINE VISUALIZED IN THE BASAL GANGLIA OF LIVING MAN [J].
GARNETT, ES ;
FIRNAU, G ;
NAHMIAS, C .
NATURE, 1983, 305 (5930) :137-138
[9]
A COMPARISON OF CLINICAL AND PATHOLOGICAL FEATURES OF YOUNG-ONSET AND OLD-ONSET PARKINSONS-DISEASE [J].
GIBB, WRG ;
LEES, AJ .
NEUROLOGY, 1988, 38 (09) :1402-1406
[10]
GLOBE LI, 1991, NEUROLOGY, V41, P168